Sihuan Pharmaceutical Holdings Group Ltd.announced that the Benapenem, being a Category 1.1 new drug developed by the KBP BioSciences received the Approval for Clinical Studies from the State Food and Drug Administration.
Sihuan Pharmaceutical Holdings Group Ltd.announced that the Benapenem, being a Category 1.1 new drug developed by the KBP BioSciences received the Approval for Clinical Studies from the State Food and Drug Administration.
16 January 2013, Sihuan Pharmaceutical Holdings Group Ltd.announced that the new Category 3.1 drug, the Nalmefene Hydrochloride Injection received a new drug certificate and approval for production (2012S00818) from the State Food and Drug Administration.
Sihuan Pharmaceutical Holdings Group Ltd. announce that it has entered into a collaboration agreement with NeuroVive Pharmaceutical AB (“NeuroVive”), a leading international mitochondrial pharmaceutical development company, to develop two innovative products, CicloMulsion® and NeuroSTAT®.
Sihuan Pharmaceutical Holdings Group Ltd. announce that it has entered into a collaboration agreement with NeuroVive Pharmaceutical AB to develop two innovative products, CicloMulsion® and NeuroSTAT®.
Sihuan Pharmaceutical Ranks 4th in Dividend Yield and 3th in Sales Growth Among “Top 100 HK-listed Companies 2012” Basic Sub-list
Select
